Navigation Links
GVHD in Medical News

REGiMMUNE to present GvHD data at the 50th ASH Annual Meeting

Mountain View, CA December 5, 2008 REGiMMUNE Corporation, a privately held biopharmaceutical company focused on developing technologies and products for immune disorders, will present preclinical data on the company's potential therapeutic treatment for Graft versus Host Disease (GvHD) at the Am...

TNF Protein Can Predict GVHD Bone Marrow Transplant Recipients

The outcome of bone marrow transplant could be determined in just one week by measuring levels of a protein called tumor necrosis factor (TNF). // The inflammatory marker can help doctors identify which patients will develop graft vs. host disease (GVHD), the most commonly observed complication fol...

DOR BioPharma Appoints Christopher P. Schnittker, CPA, as Vice President of Administration and Controller

...nfirmatory Phase 3 clinical trial of orBec(R) for the treatment of acute GI gvhd and a Phase 1/2 clinical trial of DOR201 in radiation enteritis in the seco...nt factors which may affect the future use of orBec(R) for gastrointestinal gvhd include the risks that: the FDA's requirement that DOR conduct additional c...

Damon Runyon Cancer Research Foundation awards $2.7M to 7 top young clinical investigators

... disease (GvHD) in cancer patients treated with bone marrow transplantation. His hypothesis is that regulatory T cells (Treg) can be used to suppress gvhd while preserving beneficial anti-tumor immunity. This work could have significant translational implications by reducing GvHD-associated mortality, t...

DOR BioPharma Announces Potential $30 Million North American Partnership Agreement with Sigma-Tau Pharmaceuticals for orBec(R) in the Treatment of Graft-versus-Host Disease

...dpoints such as the proportion of patients free of gvhd at Day 50 (p-value 0.05) and Day 80 (p-value 0.005...he clinically relevant determination of whether GI gvhd patients at Day 30 (the end of treatment) had a durable gvhd treatment response as measured by whether or not t...

UNC study hints at new approaches to prevent transplant rejection

...lung and skin. Not only did these findings implicate TH17 cells in the disease, but they also generated one of the first mouse models to display acute gvhd skin changes consistent with the most common manifestations of the disease in humans. Having identified the role TH17 cells play in the disease, ...

New Interventional Radiology Treatment Shows Hope for People With Complications from Bone Marrow, Stem Cell Transplants

...ment appears to be safe and effective in combating gvhd -- with about 40 percent of the patients showing c... Annual Scientific Meeting in Washington, D.C. gvhd is a common complication of an allogeneic bone mar...n, according to the National Institutes of Health. gvhd is the term used when a donor's immune cells attac...

New IDSA Clinical Practice Guidelines Recommend NOXAFIL(R) (Posaconazole) for Antifungal Prophylaxis in Certain High-Risk Patients

...ts 13 years of age and older who are at high risk of developing these infections due to being severely immunocompromised, such as HSCT recipients with gvhd or those with hematologic malignancies with prolonged neutropenia from chemotherapy. In October 2006, the FDA approved NOXAFIL Oral Suspension for t...

Kiadis Pharma Announces Successful Completion of Rhitol(TM) Phase II Clinical Study

...e outcome of this study and the potential shown by Rhitol(TM). This product would fulfill a significant unmet medical need since patients with chronic gvhd resistant or intolerant to immunosuppressive drugs have no other standard treatment option available to them and this disease can subsequently develop...

ATIR Classified as "Cell Based" Medicinal Product by the EMEA

...s Pharma. About ATIR ATIR is designed to prevent life-threatening acute gvhd by eliminating the immune cells from the donor graft that otherwise attack ...wing rapid and safe donor immune reconstitution post transplantation. Acute gvhd is a major complication of allogeneic bone marrow transplantations. By prev...
GVHD in Medical Technology

DOR BioPharma Receives EMEA Agreement on the Design of its Confirmatory Phase 3 Clinical Trial of orBec(R) in GI GVHD

PRINCETON, N.J., June 9 /PRNewswire-FirstCall/ -- DOR BioPharma, Inc. (DOR or the Company) (OTC Bulletin Board: DORB), a late-stage biopharmaceutical company, announced today that it has received Protocol Assistance feedback from the European Medicines Agency (EMEA) on the design of its confirmato...

DOR BioPharma, Inc. Executes $400,000 Equity Investment Agreement With Numoda Corporation

...nfirmatory Phase 3 clinical trial of orBec(R) for the treatment of acute GI gvhd and a Phase 1/2 clinical trial of DOR201 in radiation enteritis in the seco...nt factors which may affect the future use of orBec(R) for gastrointestinal gvhd include the risks that: the FDA's requirement that DOR conduct additional c...

Kiadis Pharma Announces Positive Clinical Results for ATIR(TM) in Mismatched Bone Marrow Transplantations

...titution following a mismatched bone marrow transplantation. Nineteen end stage blood cancer patients were treated with no cases of grade III/IV acute gvhd occurring within the first 100 days after ATIR(TM) infusion, showing the feasibility and tolerability of the addition of ATIR(TM) in combination with ...

Kiadis Pharma Announces Collaboration With the Julius Maximilians University of Wurzburg, Germany

.... About ATIR(TM) ATIR(TM) is designed to prevent life-threatening acute gvhd by eliminating the immune cells from the donor graft that otherwise attack ...wing rapid and safe donor immune reconstitution post transplantation. Acute gvhd is a major complication of allogeneic bone marrow transplantations. By prev...

DOR BioPharma Announces Publication Describing Results of Its Multivalent Botulinum Toxin Vaccine BT-VACC

...rding the potential use of orBec® for the treatment of gastrointestinal gvhd and the prospects for regulatory filings for orBec®. Where possible, DO... factors which may affect the future use of orBec® for gastrointestinal gvhd include the risks that: because orBec® did not achieve statistical sign...

DOR BioPharma Announces Issuance of European Patent for Its Oral Multivalent Botulinum Toxin Vaccine BT-VACC

...rding the potential use of orBec® for the treatment of gastrointestinal gvhd and the prospects for regulatory filings for orBec®. Where possible, DO... factors which may affect the future use of orBec® for gastrointestinal gvhd include the risks that: because orBec® did not achieve statistical sign...
GVHD in Medical Dictionary

Graft Versus Host Disease

...lant against the patient", or " Graft - versus - Host " reaction. The complication is called " Graft - versus - Host Disease " (GvHD). What Types Of gvhd Exist? ... What is the risk for developing chronic graft - vs .- host disease (GVHD) after transplant? ... Diagnosis and Clinical Management...

Gastrointestinal

...e latest gastrointestinal , gastroenterology news headlines ... GastroIntestinal ... For OrBec(R) For The Treatment Of Chronic Gastrointestinal gvhd ... From screening and prevention to treatment of advanced gastrointestinal cancer, Fox Chase Cancer Center offers comprehensive care G...
GVHD in Biological News

Predicting acute GVHD by gene expression could improve liver stem cell transplant outcomes

Tampa, Fla. (July 21, 2008) Many cell transplants involve the use of stem cells from another human being (known as an allograft), which raises the major concern of the potential for acute graft-versus-host disease (GVHD). GVHD occurs when an immune response is elicited by the grafted cells agains...

REGiMMUNE presents enhanced efficacy data in preclinical transplantation models

...ts in the skin transplant model over Sirolimus single treatment. Likewise, gvhd mortality was reduced by the combination treatment. In addition, the combin...plans to file an Investigational New Drug (IND) for the prevention of acute gvhd associated with bone marrow transplantation later this year. The poster ...

U of M begins nation's first clinical trial using T-reg cells from cord blood in leukemia treatment

...ife-threatening graft-versus-host-disease (GVHD). gvhd occurs when the immune cells within the donated cells attack the body of the transplant recipient. gvhd causes one-third of deaths after transplant. Rese...dels, T-regs will be a powerful therapy to prevent gvhd and enhance engraftment in transplant patients. O...
GVHD in Biological Technology

DOR BioPharma Receives FDA Orphan Drug Designation for orBec(R) for the Treatment of Chronic Gastrointestinal GVHD

PRINCETON, N.J., Aug. 4 /PRNewswire-FirstCall/ -- DOR BioPharma, Inc., (OTC Bulletin Board: DORB) (DOR or the Company), a late-stage biopharmaceutical company, announced today that the Office of Orphan Products Development of the United States Food and Drug Administration (FDA) has granted Or...

DOR BioPharma Announces Issuance of European Patent for its LPM(TM) Oral Drug Delivery Technology

...nfirmatory Phase 3 clinical trial of orBec(R) for the treatment of acute GI gvhd and a Phase 1/2 clinical trial of DOR201 in radiation enteritis in the seco...nt factors which may affect the future use of orBec(R) for gastrointestinal gvhd include the risks that: the FDA's requirement that DOR conduct additional c...

DOR BioPharma Announces Publication of orBec(R) Clinical Pulmonary Data in Bone Marrow Transplantation

... that were observed were clearly of benefit to the gvhd patients," said Brian L. Hamilton, MD, PhD, Chief ...inal manifestation of GVHD, the organ system where gvhd is most frequently encountered and highly problema...Bec(R) is formulated for oral administration in GI gvhd patients as a single product consisting of two tab...

DOR BioPharma Reports 1st Quarter 2009 Financial Results and Reviews Recent Accomplishments

...firmatory Phase 3 clinical trial of orBec(R) in GI gvhd under a Special Protocol Assessment (SPA) with the...al trial of orBec(R) for the treatment of acute GI gvhd and a Phase 1/2 clinical trial of DOR201 in radiat...ct the future use of orBec(R) for gastrointestinal gvhd include the risks that: the FDA's requirement that...

Kiadis Pharma Reports ATIR(TM) Clinical Data, Further Supporting its Potential in Mismatched Bone Marrow Transplantations

... transplant procedures. Nevertheless, no cases of severe grade III/IV acute gvhd occurred after ATIR(TM) infusion. Furthermore, the clinical data showed a r... adequate immune reconstitution in combination with the prevention of acute gvhd in bone marrow transplantations using a mismatched donor. Dr. Denis-...

DOR BioPharma Reports Year-End 2008 Financial Results and Reviews Recent Accomplishments

...key personnel to execute new clinical trials in GI gvhd and radiation enteritis. We are looking forward t...al trial of orBec(R) for the treatment of acute GI gvhd and a Phase 1/2 clinical trial of DOR201 in radiat...ct the future use of orBec(R) for gastrointestinal gvhd include the risks that: the FDA's requirement that...

DOR BioPharma Appoints Gregg Lapointe, CPA, MBA, to its Board of Directors

...nfirmatory Phase 3 clinical trial of orBec(R) for the treatment of acute GI gvhd and a Phase 1/2 clinical trial of DOR201 in radiation enteritis in the firs...nt factors which may affect the future use of orBec(R) for gastrointestinal gvhd include the risks that: the FDA's requirement that DOR conduct additional c...

DOR BioPharma Appoints Brian L. Hamilton, MD, PhD as Chief Medical Officer

...on. His research focus was in the immunobiology of gvhd in an animal model. He also spent several years as...3 completion in GI GVHD. His specific expertise in gvhd will be vital to the successful interaction betwee...al trial of orBec(R) for the treatment of acute GI gvhd and a Phase 1/2 clinical trial of DOR201 in radiat...

Stem Cell Transplantation Research at The Cancer Center at Hackensack University Medical Center Aims to Develop 'Designer' Transplants

... uses stem cells removed from a donor) is graft-versus-host disease (GVHD). gvhd is a potentially fatal complication that can occur when mature donor T cell...destroy residual cancerous cells while avoiding or controlling the T cells' gvhd response." Dr. Friedman continues: "Our Vß spectratype analysis is a powe...

Kiadis Pharma Receives Orphan Drug Designation for Rhitol(TM) From the FDA

...velopment as a treatment for patients with chronic gvhd resistant or intolerant to immunosuppressive agent...TM) treatment targets activated T cells that cause gvhd and results in immune modulation within patients w... achieve disease remission. About chronic GvHD gvhd is a condition that can develop after allogeneic b...
Other Tags
(Date:3/29/2015)... March 29, 2015 Adults who are ... promote nationally on the web can now use the ... insurance quotes can now be explored while researching the ... , Learning the differences between what a term policy ... a challenge for some men and women. Insurers typically ...
(Date:3/29/2015)... Chicago, IL (PRWEB) March 29, 2015 ... Foundation for Women’s Cancer announce today that ... 2015 recipient of the Claudia Cohen Research Foundation Prize ... presented at the Society of Gynecologic Oncology 46th Annual ... is Director of the Cedars-Sinai Women’s Cancer Program at ...
(Date:3/29/2015)... Washington, D.C. USA (PRWEB) March 29, 2015 ... Afro Health Link platform provides basic health ... them the opportunity to discuss these challenges as ... them. Afro Health Link addresses six medical conditions ... and encourage users to engage in conversations around ...
(Date:3/29/2015)... 29, 2015 North American Seminars receives ... Online Continuing Education Courses . , Utilizing ... CME - TPTA, approval # 56399TX      , ... the shoulder complex - 10.5 hours - Texas Board ... Examination and Treatment of the SI Joint - 10 ...
(Date:3/28/2015)... 2015 Coffee could not only perk you ... from gum disease, researchers have found. , They found that ... Coffee contains antioxidants. Antioxidants fight gum disease. Does coffee, then, ... Boston Univ. Henry M. Goldman School of Dental Medicine explored ... issue of the Journal of Periodontology. , “This is the ...
Breaking Medicine News(10 mins):Health News:Permanent Life Insurance Quotes Now Offered Through Web Search System at Insurer Website Online 2Health News:Dr. Beth Y. Karlan Named Recipient of the Claudia Cohen Research Foundation Prize for Outstanding Gynecologic Cancer Researcher 2015 2Health News:Dr. Beth Y. Karlan Named Recipient of the Claudia Cohen Research Foundation Prize for Outstanding Gynecologic Cancer Researcher 2015 3Health News:Dr. Beth Y. Karlan Named Recipient of the Claudia Cohen Research Foundation Prize for Outstanding Gynecologic Cancer Researcher 2015 4Health News:Krame Health Solutions Announces Release of AfroHealthLink, an Interactive Health Resource Center Tailored to Individuals of African & Caribbean Descent Around the World 2Health News:Krame Health Solutions Announces Release of AfroHealthLink, an Interactive Health Resource Center Tailored to Individuals of African & Caribbean Descent Around the World 3Health News:New Research Impliments Coffee May Help Fight Gum Disease and Increasing Benefits With Tylers Coffee 2
(Date:3/10/2015)... March 10, 2015  NXT-ID, Inc. (NASDAQ: ... "Company"), a biometric authentication company focused on the ... smart wallet has been named the "Number One ... Rethink Modern ( http://www.rethinkmodern.com/ ) is ... your home and lifestyle that have a unique function ...
(Date:3/3/2015)... , March 3, 2015 ... provider of advanced cryogenic logistics solutions for ... immunotherapies, stem cells, cell lines, clinical research ... medicine, today announced the expansion of its ... Centers, ("Fred Hutch") Clinical Research Division ...
(Date:3/2/2015)... 2015   Neurotechnology , a provider of high-precision ... SentiGaze Software Development Kit (SDK). The SentiGaze algorithm ... off-the-shelf webcams to track eye movements and generate heatmaps ... Heatmaps can be used for applications such as analysis ... The SDK can also be used to develop interfaces ...
Breaking Biology News(10 mins):NXT-ID's Wocket Smart Wallet Named Number One Best Tech Gift for 2015 by Rethink Modern 2NXT-ID's Wocket Smart Wallet Named Number One Best Tech Gift for 2015 by Rethink Modern 3NXT-ID's Wocket Smart Wallet Named Number One Best Tech Gift for 2015 by Rethink Modern 4Cryoport, Inc. Expands Support of Fred Hutchinson Cancer Research Center's Clinical Research Division 2Cryoport, Inc. Expands Support of Fred Hutchinson Cancer Research Center's Clinical Research Division 3Neurotechnology Releases SentiGaze SDK for Eye Movement Tracking Using Ordinary Webcams 2Neurotechnology Releases SentiGaze SDK for Eye Movement Tracking Using Ordinary Webcams 3
Other Contents